121 related articles for article (PubMed ID: 15955056)
1. Pharmacology of vascular endothelium. Delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Gryglewski RJ
FEBS J; 2005 Jun; 272(12):2956-67. PubMed ID: 15955056
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
Chłopicki S; Gryglewski RJ
Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
[TBL] [Abstract][Full Text] [Related]
3. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins.
Gryglewski RJ; Uracz W; Swies J; Chlopicki S; Marcinkiewicz E; Lomnicka M; Madej J
Ann N Y Acad Sci; 2001 Dec; 947():229-45; discussion 245-6. PubMed ID: 11795271
[TBL] [Abstract][Full Text] [Related]
4. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
[TBL] [Abstract][Full Text] [Related]
5. Protection of endothelial function.
Spieker LE; Lüscher TF
Handb Exp Pharmacol; 2005; (170):619-44. PubMed ID: 16596817
[TBL] [Abstract][Full Text] [Related]
6. Restoring the dysfunctional endothelium.
Osto E; Coppolino G; Volpe M; Cosentino F
Curr Pharm Des; 2007; 13(10):1053-68. PubMed ID: 17430168
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
Tschudi MR; Noll G; Lüscher TP
Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
[TBL] [Abstract][Full Text] [Related]
8. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitors: Is the endothelium the main target?
Puddu P; Puddu GM; Muscari A
Cardiology; 2001; 95(1):9-13. PubMed ID: 11385185
[TBL] [Abstract][Full Text] [Related]
10. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
Lüscher TF; Yang Z
Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
Yamakuchi M; Greer JJ; Cameron SJ; Matsushita K; Morrell CN; Talbot-Fox K; Baldwin WM; Lefer DJ; Lowenstein CJ
Circ Res; 2005 Jun; 96(11):1185-92. PubMed ID: 15905463
[TBL] [Abstract][Full Text] [Related]
12. [Role of the endothelium in the control of vascular motility: physiologic aspects and physiopathologic implications in cardiovascular diseases].
Limone P; Boeri E; Molinatti GM
Minerva Med; 1993 Oct; 84(10):499-505. PubMed ID: 8247303
[TBL] [Abstract][Full Text] [Related]
13. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function and bradykinin in humans.
Hornig B; Drexler H
Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
Landmesser U; Drexler H
J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
[TBL] [Abstract][Full Text] [Related]
16. The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade.
Buczko W; Matys T; Kucharewicz I; Chabielska E
J Physiol Pharmacol; 1999 Dec; 50(4):499-507. PubMed ID: 10639001
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin-mediated protection by angiotensin-converting enzyme inhibitors against injury of aortic endothelium by free radicals.
Liao DF; Chen X
Cardioscience; 1992 Jun; 3(2):79-84. PubMed ID: 1379480
[TBL] [Abstract][Full Text] [Related]
18. Endothelial function and the kidney. An emerging target for cardiovascular therapy.
Rabelink TJ; Koomans HA
Drugs; 1997; 53 Suppl 1():11-9. PubMed ID: 9034751
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities in the pharmacologic prevention of age-related macular degeneration].
Fischer T
Orv Hetil; 2008 Jan; 149(3):121-7. PubMed ID: 18194920
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelium and atherosclerosis.
Libby P; Aikawa M; Jain MK
Handb Exp Pharmacol; 2006; (176 Pt 2):285-306. PubMed ID: 16999230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
